Sanofi to Acquire Blueprint Medicines in $9.5 Billion Deal, Expanding Rare Immunological Disease Portfolio and Deepening Immunology Pipeline In a landmark move to expand its presence in rare immunological diseases and strengthen its early-stage pipeline, French pharmaceutical giant Sanofi announced…
Novartis Highlights Kisqali’s Promise in Reducing Recurrence Risk for Younger Patients with Early Breast Cancer at ASCO 2025 At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Novartis unveiled new insights from a subgroup analysis of its pivotal…
AstraZeneca’s Camizestrant Shows Landmark Efficacy in Advanced HR-Positive Breast Cancer with ESR1 Mutations in Phase III SERENA-6 Trial In a pivotal breakthrough for hormone receptor (HR)-positive, HER2-negative advanced breast cancer, AstraZeneca’s investigational selective estrogen receptor degrader (SERD), camizestrant, has demonstrated…
AstraZeneca’s Imfinzi-Based Regimen Shows Significant Benefit in Early Gastric and GEJ Cancers in Phase III MATTERHORN Trial AstraZeneca has reported highly promising results from its Phase III MATTERHORN trial, showcasing the potential of its immunotherapy drug Imfinzi (durvalumab) to transform…
Roche Reports Promising Two-Year Results for Fenebrutinib in Relapsing Multiple Sclerosis, Maintaining Disease Control and Halting Disability Progression Roche has released encouraging new long-term data from its investigational Bruton’s tyrosine kinase (BTK) inhibitor, fenebrutinib, in the treatment of relapsing multiple…
Merck Reports Encouraging Early Data for Investigational KRAS G12C Inhibitor MK-1084 in Phase 1 Trial for Advanced Colorectal and Lung Cancers Merck known as MSD outside the United States and Canada, has announced promising early results from its ongoing KANDLELIT-001…
AbbVie and the Chicago Cubs Launch Multi-Year “Striking Out Cancer” Campaign to Support Cancer Awareness and Research In a bold and heartfelt effort to turn America’s favorite pastime into a platform for cancer advocacy, AbbVie,a global biopharmaceutical company headquartered in…
Teva Embarks on Acceleration Phase of “Pivot to Growth” Strategy at 2025 Innovation & Strategy Day, Signaling Renewed Focus on Biopharmaceutical Leadership and Long-Term Shareholder Value Teva Pharmaceutical Industries Ltd.one of the world’s leading manufacturers of generic and specialty medicines,…
China Accepts New Drug Application for Shionogi’s Naldemedine to Treat Opioid-Induced Constipation Shionogi & Co., Ltd., a leading Japanese pharmaceutical company headquartered in Osaka, has announced a key regulatory milestone for its gastrointestinal therapeutic, naldemedine tosilate. The New Drug Application…
Astellas Secures Global Rights to Evopoint’s Promising CLDN18.2-Targeting Antibody-Drug Conjugate XNW27011 in Strategic Oncology Expansion In a strategic move that reinforces its commitment to precision oncology, Astellas Pharma Inc. has entered into an exclusive license agreement with Evopoint Biosciences Co.,…
Intellia Grapples with Safety Questions in ATTR Gene Editing Trial Amid Broader Sector Scrutiny Intellia Therapeutics’ stock took a steep dive Thursday morning, shedding approximately 26% of its value after the company disclosed a serious adverse event in its ongoing…
CVS Health Files Federal Lawsuit to Halt Arkansas’ Act 624, Citing Harm to Patients, Jobs, and Healthcare Access On May 29, 2025, CVS Health® filed a federal lawsuit seeking to overturn Arkansas’ controversial Act 624, a newly enacted law that…